|
楼主 |
发表于 2008-11-20 14:22:40
|
显示全部楼层
120-7-第七节 抗疟药的用药原则
前已提到,视网膜的毒性反应限制抗疟药的剂量。提高剂量,虽可提高疗效,然而毒性反应也相应提高。当前国内外常用的剂量为:经氯喳400mg/d,氯喳250mg/d。如按体重计算,每日剂量分别为6.5mg/kg和4mg/kg。把剂量控制在这种水平以下,一般是比较安全的。但是因为服药时间很长,累积剂量很高,也有视网膜病变的可能性。定期做视野和眼底等检查,能及早发现早期的轻微病变,及时停药。因此,眼科检查已成为常规(表120一2).4 Q6 O& D) {+ m' T: y) M+ C- k
) r6 Y: _9 E, d5 k( z
) Y6 Y% n! b* q+ Z9 Z% _' Z120-2A.jpg1 V: ]3 P" U$ {
0 O) a+ F% b- l4 `: T0 t
8 V+ N! p/ `" A
按照表120一2中规定,病人在服药前应先做视野检查,确定病人服药前的视野基线,然后每6个月做一次眼科检查。如检查中发现任何一种异常变化,立即停药,可避免受监察病人发生严重的视网膜病。由于病人接受抗疟药初期副作用较多,疗效又不能很快显示,如病人对副作用能耐受的话,应劝病人坚持服药满6个月,再决定是否停药还是继续治疗。显效后继续用到病情缓解,然后适当减量,控制病情在稳定期。
1 n% `4 \2 K$ K# Q8 C& j
$ j& y* \: t; B+ \' V 综上所述,抗疟药治疗各种风湿病都有一定疗效,副作用较其他抗风湿病药为轻。采取控制剂量和定期眼科检查等措施后,眼视网膜病变的发生率很低,因此,国内外仍被广泛应用。 ! b _% o s/ G
( 叶益新 张江林 黄 烽 )% q/ E* }$ x* y3 A6 N
参考文献:
/ K7 [. _( |9 Z5 h
4 R, }; F& W7 @& ^# H* G, q 叶益新,汪中.抗疟药.见:蒋明,朱立平,林孝义主编,风湿病学.第一版,北京:科学出版社,1995. 1798一1806 # C# o- u- u1 I& F. E6 B. H
* y& F) Q& V$ z! q) P, S" g 余碧娥,方丽.经抓唆的眼科不良反应分析.中国新药与临床杂志,2001. 20(3):235一236
7 T8 W* ] ~2 u' _, U- }' ?; i* H# Q* ~* K" H1 A, @3 c
Rynes RI. Antimalarial drugs. In: Shaun R, Edward DH,Clement BS et al eds, Kelley's Textbook of Rheumatology. 6thed, Philadelphia: Saunders, 2001.859一867 3 l5 Y; }, {+ D0 g; s
# y' c) g ?2 b+ \! n Avina-Zubieta 1A, Galindo-Rodriguez G, Newman S et al.Long-term effectiveness of antimalarial drugs in rheumatic dis-eases. Ann Rheum Dis, 1998. 57(10):582一587
8 |$ @2 E5 `$ f
: t3 z2 {; t [2 U& \ Biasi D, Caramaschi P, Carletto A, et al. Combination ther-apy with hydroxychloroquine, gold sodium thiomalate andmethotrexate in early rheumatoid arthritis. An open 3-yearstudy. Clin Rheumatol, 2000. 19(6):505一507 5 z0 M% @8 G; K' ~! g
{4 [- i* `7 q) W Block 7A. Hydroxychroloquine and retina safety. Lancet,1998. 351:771
, J& h% ]( D" C, m7 [: V4 H, J9 r- j5 k4 j) d/ Y- V- }3 c# `
Borden MB, Parke AL. Antimalarial drugs in systemic lupuserythematosus: use in pregnancy. Drug Saf 2001. 24(14):1055一1063
1 `1 v" Y! ` F2 l0 m% a& Q: |) {% z8 L
Case JP. Old and new drugs used in rheumatoid arthritis: ahistorical perspective partl:the older drugs. Am J Therapeutics,2001. 8:123一143 9 o( K8 ^4 r5 C X$ C
$ u- V# l* j* E
Clegg D O, Dietz F, Duffy J, et al. Safety and efficacy ofhydroxychloroquine as maintenance therapy for rheumatoid arthri-tis after combination therapy with methotrexate and hydroxy-chloroquine. J Rheumatol, 1997. 24:1896一1902
* m/ m7 q" u4 ^+ i" U9 W0 e# {- N/ f4 g% l6 B& n) u
Coutinho MB, Duarte 1. Hydroxychloroquine ototoxicity ina child with idiopathic pulmonary haemosiderosis. Int J PediatrOtorhinolaryngol 2002.62(l):53一57
$ c3 ?' k, b4 |& T% p% f
9 O/ C, |! l+ j) k Duncan MR, Capell HA. The use of antimalarials in combi-nation with other disease modifying agents in RA一the British ex-perience. Lupus, 1996.5 Suppl 1:S50一58 8 V+ e' r9 ~% R, S+ R6 `
" w" _5 f0 ]* Y5 F: n/ b Felson DJ,Anderson JJ, Meenan RF. The comparative effi-cacy and toxicity of second-line drugs in rheumatoid arthritis. Re-sults of two meta-analyses. Arthritis Rheum, 1999. 33: 1449一1461. 8 o8 i& s: K5 A9 b7 X' R
1 x: ]. q3 t' B" `
Fox R. Anti-malarial drugs: possible mechanisms of actionin autoimmune disease and prospects for drug development. Lupus, 1996. 5 Suppl 1: S4一10
. D8 r' n& ]3 C/ q8 ]/ a* I% F. C; ?) W0 s7 f
Fox RI, Dixon R, Guarrasi V, et al. Treatment of primarySjogren' s syndrome with hydroxychloroquine: a retrospective,open-label study. Lupus, 1996. 5 Suppl 1:S31一36
0 K' ?( q2 r/ s% @1 Z. [( Y7 G
2 `4 [* z5 p# d, `9 \/ Q2 n Furst DE. The combination of methotrexate, sulfasalazineand hydroxychloroquine is highly effective in rheumatoid arthri-tis. Clin Exp Rheumatol, 1999. 17(1):39一40 ( Z1 {9 _7 v0 h, M: \
( U* P% Q- W8 C4 D9 k+ \
Garrood T, Scott DL. Combination therapy with diseasemodifying anti-rheumatic drugs in rheumatoid arthritis. BioDrugs2001. 15(8):543一561
( B" }3 R8 T9 k7 E2 n' ^' d$ f! w- h X$ X" J# }! i
Goekoop YP, Allaart CF, Breedveld FC, et al. Combinationtherapy in rheumatoid arthritis. Curr Opin Rheumatol, 2001. 13(3):177一1831 _- r1 m7 I; `1 n( {$ _. [0 H3 ^
" M4 B0 P1 f" L/ |2 y8 {$ J+ b- C Guedira N, Hajjaj-Hassouni N, Srairi JE, et al. Third-de-gree atrioventricular block in a patient under chloroquine therapy.Rev Rhum E心 ,1998. 650):58一62
1 i( {' B& E+ k' ^1 A
# K* F- ]# V7 m) T Hawley DJ, Wolfe F, Pincus T. Use of combination therapyin the routine care of patients with rheumatoid arthritis: physicianand patient surveys. Clin Exp Rheumatol, 1999. 17 ( 6 Suppl18):S78一82 : U8 ~" w, e. O" }6 w+ ]" Y
: I6 Q0 b, i Y8 m: A Janssen NM, Genta MS. The effects of immunosuppressiveand anti-inflammatory medications on fertility, pregnancy, andlactation. Arch Intern Med, 2000. 160(5):610一619 ! t! P9 C5 R4 b+ [1 B
0 L: r) V* E* L Jones SK. Ocular toxicity and hydroxychloroquine: guide-lines for screening. Br J Dermatol,1999. 140(l) : 3一7
' P( Y: q2 ~% s" g. i9 q$ A C
7 K" ^ t X! m; ~; A6 ` Keyszer G, Keysser C, Keysser M. Efficacy and safety of acombination therapy of methotrexate, chloroquine and cyclophos-phamide in patients with refractory rheumatoid arthritis: resultsof an observational study with matched-pair analysis. ClinRheumatol, 1999. 18(2) :145一151 " O$ c, f: G E+ p1 y4 c
2 H3 Z5 ~+ O- e6 G. \% x) h& |% P1 J" P; Q
Koren G. Antimalarial drugs for rheumatoid disease duringpregnancy. Can Fam Physician, 1999. 5:2869一287。
9 T( d# j" e. m" j" s$ E8 h8 M5 j; J; ]: Q+ F% ^
Kremer JM. Rational use of new and existing disease-modi-fying agents in rheumatoid arthritis. Ann Intern Med, 2001. 134(8):695一706
& f2 {( S! e6 l, p: y3 x' _3 }% @+ {/ W: T) R1 T
Nayak V, Esdaile JM. The efficacy of antimalarials in sys-temic lupus erythematosus. Lupus 1996. 5 Suppl 1:S23一27
X, K! @! a" r0 J7 u R
# X5 ]# B7 L' M. y5 N8 L O'Dell JR, Blakely KW, Mallek JA, et al. Treatment ofearly seropositive rheumatoid arthritis: a two-year, double-blindcomparison of minocycline and hydroxychloroquine. ArthritisRheum, 2001. 44(10):2235一2241 2 i. ]5 E0 A. y, {6 x
2 V4 G; \% R) ]8 X3 C" D1 m O'Dell JR. Triple therapy with methotrexate, sulfasalazine,and hydroxychloroquine in patients with rheumatoid arthritis.Rheum Dis Clin North Am, 1998. 24(3) :465一477 & X# O$ B5 d) E0 k
: w- I: _$ J, o# Q4 l# T5 p' y O} Dell JR. Combination DMARD therapy with hydroxy-chloroquine, sulfasalazine, and methotrexate. Clin Exp Rheuma-tol, 1999.17(6 Suppl 18):S53一58 / s2 ?/ u0 N; ^+ ]& L- C- q
+ J' E: b4 o1 N3 | Ostensen M, Ramsey-Goldman R. Treatment of inflamma-tory rheumatic disorders in pregnancy: what are the safest treat-ment options? Drug Saf, 1998. 19(5) :389一41。' u8 e8 `5 t8 B8 w. D6 S
( ]+ Z- _) @. z4 z. W/ }7 G9 M$ R Parke AL, Rothfield NF. Antimalarial drugs in pregnancy一the North American experience. Lupus, 1996 . 5 Suppl 1: S67一69
% E B0 F6 i/ m' o- B& K- ]" z2 A. k9 q$ d& Y
Pincus T, O} Dell JR, Kremer JM. Combination therapywith multiple disease-modifying antirheumatic drugs in rheuma-toid arthritis: a preventive strategy. Ann Intern Med, 1999. 131(10):768一774 ' _! T0 V1 F A& S* f4 c
: q. n" ~- Y- `% Q0 D. o% ?( j Riise T, Jacobsen BE,Gran JT. Changes in therapy ofrheumatoid arthritis during the period 1979 to 1996. Scand JRheumatol, 2001. 30(4):199一202
9 N; H, \) |3 _8 I' s- n9 e4 P" j' B- j
Rynes RI. Ophthalmologic considerations in using antimalar-ials in the United States. Lupus, 1996. 5 Suppl 1:573一74
; [- [9 H" S+ p) f+ L
3 f& u1 C; O( [- M Spalton DJ. Retinopathy and antimalarial drugs-the Britishexperience. Lupus, 1996. 5 Suppl1:S70一72
3 l; c/ K* ^& j* c
3 }% ?& Q: Y% _. D Seckin U, zoran A, Ikinciogullari A. Hydroxychloroquine o-totoxicity in a patient with rheumatoid arthritis. Rheumatol Int,2000. 19:203一204
& y& {! d9 G, k- u6 M% `( `% w1 K4 y; h' T
Tett SE, Cutler DJ, Beck C, et al. Concentration-effect re-lationship of hydroxychloroquine in patients with rheumatoidarthritis一a prospective, dose ranging study. J Rheumatol,2000. 27(7):1656一1660
) j) W9 m* H) B$ d% ~9 d1 O& e4 H4 m+ W3 P
Tishler M, Yaron 1, Shirazi I, et al. Hydroxychloroquinetreatment for primary Sjogren's syndrome: its effect on salivaryand serum inflammatory markers. Ann Rheum Dis, 1999. 58(4):253一256
) v% M7 x5 l T" |. B' S
1 v; B# C2 x0 l, x Tsakonas E, Fitzgerald AA, Fitzcharles MA, et al. Conse-quences of delayed therapy with second-line agents in rheumatoidarthritis: a 3 year follow up on the hydroxychloroquine in earlyrheumatoid arthritis (HERA) study. J Rheumatol, 2000. 27(3):623一629
7 r# H8 @0 R2 m) I8 Z& A* Z- t8 a+ S
van Jaarsveld CH, Jahangier ZN, Jacobs JW, et al. Toxicityof anti-rheumatic drugs in a randomized clinical trial of earlyrheumatoid arthritis. Rheumatology (Oxford) 2000. 39(12):1374一1382 : Q# v: `1 o& |" O
% L! S, U. y- d; e1 t5 `
Veinnl JP, Mai KT, Zarychanski R. Chloroquine relatescardiac toxicity. J Rheumatol, 1998. 25:1221一1225 |
|